We randomly assigned eligible patients in a @:@ ratio to receive oral afatinib ( @ mg/day ) or intravenous methotrexate ( @ mg/m ( @ ) per week ) , stratified by ECOG performance status and previous EGFR-targeted antibody therapy for recurrent or metastatic disease .